SWX:RO

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTURoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…

1 month ago
Roche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solutionRoche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solution

Roche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solution

December 18, 2024 01:00 ET  | Source: F. Hoffmann-La Roche Ltd Roche launches its cobas® Mass Spec solution, bringing mass…

3 months ago
Five-year results confirm Roches Polivy combination therapy as new standard of care for previously untreated aggressive lymphomaFive-year results confirm Roches Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Five-year results confirm Roches Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of…

3 months ago
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologiesRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and…

4 months ago